(Reuters) -The European Commission on Tuesday authorized the use of Eisai and Biogen’s drug to treat mild cognitive impairment in the early stages of Alzheimer’s disease.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas)
Brought to you by www.srnnews.com
